公开(公告)号：US08647629B2

公开(公告)日：2014-02-11

申请号：US12466222

申请日：2009-05-14

申请人： Hans-Georg Rammensee ,  Stefan Stevanovic ,  Cécile Gouttefanges ,  Toni Weinschenk ,  Peter Lewandrowski

发明人： Hans-Georg Rammensee ,  Stefan Stevanovic ,  Cécile Gouttefanges ,  Toni Weinschenk ,  Peter Lewandrowski

IPC分类号： A61K38/08 ,  A61K38/10 ,  A61K39/00 ,  C07K14/00 ,  C12P21/00 ,  A61K48/00

CPC分类号： A61K38/10 ,  A61K39/0011 ,  C07H21/00 ,  C07K7/08 ,  C07K14/4747 ,  C07K14/4748 ,  C07K14/7056 ,  C07K16/18 ,  C12N15/10 ,  C12N15/86

摘要： The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

摘要翻译： 本发明涉及用于癌症免疫治疗的肽，核酸和细胞。 本发明还涉及存活蛋白衍生的肿瘤相关细胞毒性T细胞（CTL）肽表位，其单独或与作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的其它肿瘤相关肽组合。 本发明具体涉及可衍生自人类肿瘤细胞的HLA I类和II类分子的三种新型肽序列及其变体，其可用于引发抗肿瘤免疫应答的疫苗组合物。